AstraZeneca stock edges higher after solid 2024 earnings and oncology growth

AstraZeneca stock has been trading in a range that reflects the companys transition into a higher growth oncology and biopharmaceutical profile, with the US ADR (ISIN US6549022043) on Nasdaq tracking global healthcare peers on the back of double digit revenue expansion reported for 2024 and detailed guidance for 2025. The latest full year numbers, presented in early 2025 according to the companys investor relations material, showed that AstraZeneca continued to grow across key therapeutic areas while absorbing substantial investment in research and development.

Revenue up double digits in 2024

According to the companys published 2024 results on its investor relations site, AstraZenecas total revenue for full year 2024 reached approximately $48.5 billion, representing an increase of about 12 percent compared with 2023, underlining the scale of its late stage portfolio and new launches. In the same 2024 reporting period, core earnings per share came in at around $8.00 on a constant currency basis, rising from roughly $6.65 in 2023 and illustrating how operating leverage and portfolio mix improvements translated into faster earnings growth than revenue growth.

The same 2024 report indicated that oncology remained the largest single therapy area for AstraZeneca, with oncology revenue climbing to roughly $18.5 billion for the year, up from about $16.2 billion in 2023, a year on year increase of around 14 percent driven by strong demand for targeted therapies and immuno oncology agents. Cardiovascular, renal, and metabolism medicines alongside respiratory and immunology treatments also contributed meaningfully, with the combined revenue of these franchises accounting for a substantial share of the groups non oncology turnover in 2024 and providing diversification beyond any single product line.

Oncology revenue rises about 14 percent

Within the oncology segment, several key products supported AstraZenecas 2024 performance, including targeted therapies for lung, ovarian, and breast cancer that have been gaining share in multiple markets. The companys reported revenue progression indicates that oncology has now grown to represent close to 40 percent of total group sales in 2024, compared with a little more than one third in 2022, a shift that underscores managements strategic emphasis on cancer medicines with high unmet medical need and long intellectual property tails.

Management has emphasized in its 2024 commentary that continued investment in late stage trials across oncology, cardiovascular and renal diseases, and rare diseases remains a priority, with total research and development expenses running into the high single digit billions of dollars for the year. Despite this elevated spending level, AstraZeneca still reported an improvement in its core operating margin in 2024 compared with 2023, reflecting the positive impact of scale, mix, and disciplined cost management across manufacturing and commercial operations.

In addition to revenue and earnings expansion, AstraZeneca also returned cash to shareholders via dividends declared for 2024 that, according to company communications, maintained the groups established progressive dividend policy. The combination of dividend payments and reinvestment in the pipeline is designed to balance income for shareholders with long term value creation through new medicine launches and lifecycle management of existing products.

Tagrisso, Imfinzi, and other key medicines

AstraZenecas growth in 2024 was supported by several flagship medicines, including the lung cancer treatment Tagrisso, the immuno oncology agent Imfinzi, and the diabetes and heart failure drug Farxiga, each of which generated multi billion dollar annual sales according to the companys reported segment breakdown. Tagrisso in particular has become a cornerstone therapy in first line and subsequent lines of treatment for specific forms of non small cell lung cancer, and the reported revenue growth for Tagrisso remained robust in 2024 as more patients gained access in both developed and emerging markets.

Imfinzi, which is approved for multiple indications in lung and biliary tract cancers among others, also contributed meaningfully to oncology revenue expansion, with AstraZeneca reporting double digit sales growth for the medicine in 2024 relative to 2023. Farxiga, positioned in cardiovascular and renal diseases as well as diabetes, continued to gain traction with physicians owing to its evidence base in heart failure and chronic kidney disease, and the company has highlighted its potential to remain a long duration growth driver, particularly as additional real world data confirm its clinical profile.

Alongside these established medicines, AstraZeneca continued to broaden its rare disease footprint following earlier acquisitions and integration of specialty assets, noting in its 2024 disclosures that rare disease revenue grew at a double digit rate year on year. This diversification into rare and ultra rare conditions complements the larger oncology and cardiometabolic franchises and can provide high margin contributions due to premium pricing and targeted patient populations.

Nasdaq listing and AstraZeneca stock performance

AstraZeneca has an American depositary receipt listing on Nasdaq under the symbol AZN, giving US based investors direct access to the companys equity alongside its primary listing in London. Market data from major financial portals indicate that as of early 2025 the Nasdaq traded ADR was changing hands at around $70 per share, placing AstraZeneca stock within reach of the upper half of its prior fifty two week trading range, which extended from roughly $60 to about $80 over the previous year.

Based on publicly available market capitalization figures from major quote services, AstraZenecas total equity value across its primary London listing and US ADRs was around $220 billion as of early 2025, positioning the group among the worlds largest biopharmaceutical companies by market value. On a year to date basis at that time, AstraZeneca stock had delivered a mid single digit percentage gain compared with the level at the start of 2025, a performance roughly in line with broader global pharmaceutical indices that have been influenced by interest rate expectations and healthcare policy developments.

For investors, the combination of sustained double digit revenue growth, expanding oncology and rare disease portfolios, and a sizeable dividend stream has helped support AstraZeneca stock despite ongoing competitive pressures from generics and rival innovators. The stock remains sensitive to clinical trial readouts, regulatory decisions, and pricing debates, but the companys scale and pipeline breadth provide a buffer against single product setbacks and allow management to redeploy capital toward new opportunities as older medicines mature.